Symbols

AKTS

Aktis Oncology·NASDAQ

--(--)

AKTS Profile

Aktis Oncology, Inc.

A clinical-stage oncology company

Industry

Biological Technology

Established Date

Listing Date

01/09/2026

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.aktisoncology.com

Security Type

Common stock

Office address

17 Drydock Avenue Suite 17-401 Boston Massachusetts 02210

Business

Introduction

Aktis Oncology, Inc. was incorporated under the laws of the State of Delaware in August 2020. The company is a clinical-stage oncology company that leverages its proprietary small protein platform to develop targeted radiopharmaceuticals. Its lead drug candidate [225Ac] Ac-AKY-1189 targets Nectin-4 and is currently in Phase 1 b clinical development for urothelial carcinoma and other solid tumors expressing Nectin-4.